Recurrent gliomas- a short review of literature.


Recurrent gliomas- a short review of literature.


Dr. Sudeb Mukherjee

MBBS. MD.(Medicine), DM-Post Doctorate Fellow-ICVS, IPGME&R, Kolkata-700020.


American Journal of Cancer Research and Reviews

Gliomas one of the commonest tumour account for 40-60% of all primary neoplasm of the central nervous system. Very little is known about pathological changes associated with recurrence of gliomas. Histlogical changes regarding this transformation also is not well documented. Effect of radiotherapy and chemotherapy which results in decrease in cellularity, fibrosis, thickening of vessels are also not well documented. Paired study combining both primary and recurrent gliomas are sparse. Several genetic alterations has been mentioned in the causation and pathophysiology of recurrent gliomas. Starting from overexpression to mutation of p53 to Epidermal Growth Factor(EGFR), platelet derived growth factor-α(PDGF-A),PTEN , MDM2 all have mentioned several studies. This review article describes every aspects of recurrent gliomas in short span.


Keywords: Recurrent gliomas, EGFR( Epidermal Growth Factor), p 53, platelet derived growth factor-α(PDGF-A).

Free Full-text PDF


How to cite this article:
Sudeb Mukherjee.Recurrent gliomas- a short review of literature. American Journal of Cancer Research and Reviews, 2018,2:6. DOI: 10.28933/ajocrr-2018-06-1801


References:
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO Classification of tumours of the central nervous system. IARC, Lyon. doi:10.1007/s00401-007-0243-4
2. Daumas –Duport C,Scheithauer B, O Fallon J,Kelly P(1988).Grading of astrocytomas.A simple and reproducible method.Cancer 62: 2152-2165.
3. Shaw E G, Scheithauer BW, O Fallon J R, Tazelaar H D, Davis D H, (1992) Oligodendrogliomas the Mayo clinic experience. J Neuroserg 76:428-434.
4. Robertson PL,Zeltzer PM,Boyett JM,Rorke LB,Allen JC, Geyer JR,Stanley P,Li H, Albright AL,Mcguire-Cullen P, Finlay JL,Stevens K R, Jr. , Milstein JM, Packer RJ, Wisoff J(1998). Survival and prognostic factors following radiation therapy and chemotherapy for ependymoma in children: a report of the Children’s Cancer Group. J Neurosurg 88: 695-703. DOI:10.3171/jns.1998.88.4.0695
5. Kudo H, Di S, Tamaki N, Nishida Y, Matsumoto S,(1990).Ependymoma diagnosed in the first yr of life in japan in collaboration with the International Society for Pediatric Neurosurgery.Child Nerv Syst 6:375-378.
6. Pollack IF, GersztenP C,Martinej AG,Lo KH, Schultz B, Albright AL, Janosky J, Deutsch M,(1995).Intracranial ependymomas of childhood:long term outcome and prognostic factors. Neurosurgery 37:655-666.
7. Zulch K J 1986. Brain Tumours. Their Biology and pathology. 3rd ed, Springer Verlag: Berlin Heidelber
8. Kleihues P, Ohgaki H 1999. Primary and secondary glioblastoma: from concept to clinical diagnosis. Neuro-Oncology 1: 44-51
9. Kim T S,,Halliday A L, Hedley W, Convery K,(1991) Correlates of survival and the Daumas –Duprt grading system for astrocytomas.J Neurosurg74: 27-37
10. Lee TT, Manzaro GR. 1997. Third ventricular glioblastoma multiforme: case report. Neurosurg Review 20: 291-294.
11. Anzil AP 1970. Glioblastoma multiforme with extra cranial metastasis in absence of previous craniotomy. Case report. J Neurosurg 33:88-9. DOI: 10.3171/jns.1970.33.1.0088
12. Burger PC, Heinz ER et al 1988. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68: 698-70. DOI: 10.3171/jns.1988.68.5.0698
13. Patronas NJ, Di Chiro G et al 1985. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62:816-22
14. Lantos P L,Vandenberg SR, Kleihous P .1996 Tumours of the nervous system. In: Greenfield’s Neuropathology, Graham D, Lantos P L (eds),6th edn Arnold: London. pp583-879
15. Lomax, M. E. et al. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li–Fraumeni-like family. Oncogene 14, 1869–1874 (1997). DOI:10.1038/sj.onc.1201133
16. Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855–4878 (1999)
17. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. Apr 1997;3(4):523-30. [Medline].
18. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19: 3159–3167
19. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284: 31–53.
20. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. Jun 1 2007;25(16):2288-94. DOI:10.1200/JCO.2006.08.0705
21. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997;75(9):1269-78.
22. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. Nov 1 2007;21(21):2683-710. DOI:10.1101/gad.159670
23. A M Stark, P Witzel, R J Strege, et al, J Neurol Neurosurg Psychiatry 2003 74: 779-783. doi: 10.1136/jnnp.74.6.779. DOI: 10.1136/jnnp.74.6.779
24. K C Jain*, P Chattopadhyay**,†, C Sarkar§, S Sinha** and A K Mahapatra,Departments of *Neurosurgery, **Biochemistry and §Neuropathology,All India Institute of Medical Sciences, New Delhi 110029, Indiahttp :// www.ias.ac.in /jbiosci/december1999/article12. html.
25. Gomori, Éva MD; Fulop, Zsolt MD; Meszaros, Istvan MD; Doczi, Tamas MD; Matolscy, Andras MD Journal of Neuropathology & Experimental Neurology: May 2002 – Volume 61 – Issue 5 – p 396–402
26. Elizabeth A. Maher, Cameron Brennan, Patrick Y. Wen, et alMarked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecularand Clinical Secondary Glioblastoma Entities. Cancer Res, 2006;66:11502-11513. DOI: 10.1158/0008-5472.
27. Harada K, Kurisu K, Tahara H, Tahara E, Ide T, Tahara E Department of Neurosurgery, Kanbara Hospital, Hiroshima, Fukuyama-City, Japan. neuro007@urban.ne.jp
28. Das A, Tan WL, Teo J, Smith DR Department of Neurology, National Neuroscience Institute, Singapore PMID: 12635658 [PubMed – indexed for MEDLINE]
29. Anupma Nayak, Angela Mercy Ralte, Mehar Chand Sharma, Varinder Paul Singh*, Ashok Kumar Mahapatra*, Veer Singh Mehta*, Chitra Sarkar Departments of Pathology and *Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
30. Marjut Puputti1,Olli Tynninen2,Harri Sihto1,Tea Blom3,Hanna Mäenpää1,Jorma Isola4,Anders Paetau2, Heikki Joensuu135and Nina N. Nupponen31Laboratory of Molecular Oncology, Biomedicum Helsinki; 2Department of Pathology, Helsinki University Central Hospital (HUSLAB) and University of Helsinki; 3Molecular Cancer Biology Program, University of Helsinki, Biomedicum Helsinki; 4Institute of Medical Technology, University of Tampere, Finland; and 5Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.Marjut.Puputti@hus.fiDaisuke
31. Kita,Yasuhiro Yonekawa et al. 2007. PIK3CA alterations in primary (de novo) and secondaryGlioblastomas. Acta Neuropathol 113:295–302
32. Viana-Pereira, M., Lopes, J. M., Little, S., Milanezi, F., Basto, D., Pardal, F., Jones, C., Reis-Filho, R. M. 2008. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer research, 28 (2A). pp. 91.
33. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC Department of Pathology, New York University Medical Center, New York 10016, USA. newcoe01@mcrcr.med.nyu.edu Brain Pathol. 1998 Oct;8(4):667-8.
34. Hu J, Jiang CC, Ng HK, Pang JC, Tong CY, Chen SQ Department of Neurosurgery, Huashan Hospital, Medical Center of Fudan University, Shanghai, PR China. ly045012@online.sh.cn.
35. Justin S. Smith, Issei Tachibana et al .2001. PTEN Mutation, EGFR Amplification, and Outcomein Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme. J Natl Cancer Inst;93:1246–56.
36. Fuller CE, Wang H et al.2002. High-throughput molecular profiling of high-grade astrocytomas: The utility of TMA-FISH.Journal of Neuropathology and Experimental Neurology; 61, 12; pg. 1078.
37. Heimberger AB, Suki D, Yang D, Shi W, Aldape K.Department of Neurosurgery, The Brain Tumor Center, The University of Texas M, D, Anderson Cancer Center, Houston, Texas, USA. aheimber@mdanderson.org.
38. Stark AM, Stepper W, Mehdorn HM. Department of Neurosurgery, University Medical Center of Schleswig-Holstein, Campus Kiel, Kiel, Germany.starka@nch.uni-kiel.deEur J Cancer Care (Engl). 2010 Jan 1;19(1):39-44. Epub 2009 Nov 11.
39. Stark AM, Hugo HH, Witzel P, Mihajlovic Z, Mehdorn HM. KliZentralbl Neurochir. 2003;64(1):30-6. nik für Neurochirurgie im Universitäts klinikum Kiel.